Crestor

Crestor (AstraZeneca)
Patent expiry: July 2016

2012 sales: $6.253 billion
2011 sales: $6.622 billion
Change: (6%)

Crestor remains king of the cardio hill, but time is running short for the cholesterol-reducing med. The blockbuster is already withering under the heat of generics in Canada, and with a recent patent settlement, it will face copycat rivals by May 2016. AstraZeneca ($AZN) recently struck a deal with Actavis ($ACT) and Egis to allow them to begin making generics 67 days ahead of Crestor's losing its pediatric exclusivity. Facing other patent losses and a bum short-term earnings picture, AstraZeneca has been trying to hold onto as much Crestor revenue as it can for just as long as possible.

Sales of the drug were actually up 3% in the U.S. last year to $3.164 billion but down 9% in the rest of the world to $3.089 billion. They were off 11% in Q1 2013, including a 1% nick in the U.S. One factor pressuring sales is that Pfizer's ($PFE) Lipitor, the long-time rival to Crestor, has lost patent protection, so cheap generics of that drug have flooded the market worldwide.

AstraZeneca had hoped that long-term research would demonstrate that Crestor had a performance edge over Lipitor. But though the SATURN study showed that Crestor beat Lipitor at lowering cholesterol, the AstraZeneca drug wasn't any better at keeping arteries clear--and that's the result AstraZeneca had been aiming for.

Special Report: The 15 best-selling drugs of 2012 - Crestor

For more:
AstraZeneca zaps another Crestor generic threat with Actavis settlement
AstraZeneca beats back would-be Crestor copycats

Crestor
Read more on

Suggested Articles

Imbruvica has enjoyed a nice run in previously untreated CLL over the last few years. But major competition is here in the form of AZ's Calquence.

Pennsylvania's Supreme Court revived thousands of lawsuits alleging the antipsychotic med Risperdal caused males to develop breasts.

In the asthma biologics race, there doesn't appear to be a clear favorite among Xolair, Dupixent, Fasenra and Nucala for a group of pulmonologists.